134670-30-7

Usage

Uses

Used in Pharmaceutical Industry:
6-(4-FLUOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBOXALDEHYDE is used as a key intermediate in the synthesis of new drugs for various therapeutic applications. Its unique structural features and pharmacological activities make it a valuable candidate for the development of innovative therapeutic agents.
Used in Academic Research:
6-(4-FLUOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBOXALDEHYDE is utilized as a research compound in academic settings to explore its potential applications in medicinal chemistry and drug discovery. Researchers can use 6-(4-FLUOROPHENYL)IMIDAZO[2,1-B][1,3]THIAZOLE-5-CARBOXALDEHYDE to investigate its biological activities, mechanism of action, and interactions with biological targets, contributing to the advancement of knowledge in the field.

InChI:InChI=1/C12H7FN2OS/c13-9-3-1-8(2-4-9)11-10(7-16)15-5-6-17-12(15)14-11/h1-7H

Upstream product

• 403-29-2 2-bromo-4'-fluoroacetophenone 
• 68-12-2 N,N-dimethyl-formamide 
• 7025-29-8 6-p-fluorophenylimidazo<2,1-b>thiazole 
• 5068-71-3 2-amino-3-[2-(4-fluoro-phenyl)-2-oxo-ethyl]-thiazolium; bromide 

Downstream Products

• 723341-47-7 4-{(E)-2-[6-(4-fluorophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]vinyl}pyrimidin-2-amine 
• 1257653-84-1 (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(Benzo[d][1,3]dioxol-5-yl)prop-2-en-1-one 
• 1288983-50-5 (E)-1-(biphenyl-4-yl)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)prop-2-en-1-one 
• 1336804-54-6 NSC 747111 
• 1288982-98-8 (E)-1-(3,4-dimethylphenyl)-3-(6-(4-fluorophenyl)imidazo[2,1-b] thiazol-5-yl)prop-2-en-1-one 
• 1257653-86-3 (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one 
• 1257653-78-3 (E)-3-(6-(4-fluorophenyl)-2-methylimidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1257653-72-7 (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one 
• 1288983-38-9 (E)-3-(6-(4-fluorophenyl)imidazo[2,1-b]thiazol-5-yl)-1-(naphthalen-2-yl)prop-2-en-1-one 

Relevant academic research and scientific papers

New imidazo[2,1-: B] thiazole-based aryl hydrazones: Unravelling their synthesis and antiproliferative and apoptosis-inducing potential

Herein, we have designed and synthesized new imidazo[2,1-b]thiazole-based aryl hydrazones (9a-w) and evaluated their anti-proliferative potential against a panel of human cancer cell lines. Among the synthesized compounds, 9i and 9m elicited promising cytotoxicity against the breast cancer cell line MDA-MB-231 with IC50 values of 1.65 and 1.12 μM, respectively. Cell cycle analysis revealed that 9i and 9m significantly arrest MDA-MB-231 cells in the G0/G1 phase. In addition, detailed biological studies such as annexin V-FITC/propidium iodide, DCFH-DA, JC-1 and DAPI staining assays revealed that 9i and 9m triggered apoptosis in MDA-MB-213 cells. Overall, the current work demonstrated the cytotoxicity and apoptosis-inducing potential of 9i and 9m in breast cancer cells and suggested that they could be explored as promising antiproliferative leads in the future. This journal is

DL5050, a Selective Agonist for the Human Constitutive Androstane Receptor

The constitutive androstane receptor (CAR) is a xenobiotic sensor governing the transcription of genes involved in drug disposition, energy homeostasis, and cell proliferation. However, currently available human CAR (hCAR) agonists are nonselective, which

Human constitutive androstane receptor agonist DL5016: A novel sensitizer for cyclophosphamide-based chemotherapies

The DNA alkylating prodrug cyclophosphamide (CPA), alone or in combination with other agents, is one of the most commonly used anti-cancer agents. As a prodrug, CPA is activated by cytochrome P450 2B6 (CYP2B6), which is transcriptionally regulated by the

CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER

The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The sm

Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors

The activity of a series of imidazo[2,1-b]thiazole guanylhydrazones as inhibitors of p90 ribosomal S6 kinase 2 (RSK2) is described. It was found that a small subset of compounds show both potent inhibition of RSK2 kinase activity and tumor cell growth in vitro. Detailed study of one of the most active compounds indicates a high degree of selectivity for inhibition of RSK2 compared to a spectrum of other related kinases. Selective inhibition of the MCF-7 breast tumor cell line compared to MCF-10A non-transformed cells, as well as selective inhibition of the biomarker GSK3 provides evidence that the compounds can affect the RSK2 target in cells.

Synthesis of imidazothiazole-chalcone derivatives as anticancer and apoptosis inducing agents

A new class of imidazo[2,1-b]thiazole chalcone derivatives were synthesized and evaluated for their anticancer activity. These chalcone derivatives show promising activity, with logGI50 values ranging from -7.51 to -4.00. The detailed biological aspects of these derivatives toward the MCF-7 cell line were studied. Interestingly, these chalcone derivatives induced G 0/G1-phase cell-cycle arrest, down-regulation of G 1-phase cell-cycle regulatory proteins such as cyclin D1 and cyclin E1, and up-regulation of CDK4. Moreover, these compounds elicit the characteristic features of apoptosis such as enhancement in the levels of p53, p21, and p27, suppression of NF-κB, and up-regulation of caspase-9. One of these chalcone derivatives, 3d, is potentially well suited for detailed biological studies, either alone or in combination with existing therapies. Breaking the cycle: We undertook an extensive examination of the ability of a series of new chalcone derivatives to regulate the cell cycle and to induce apoptosis in various cancer cell lines. Compound 3d is a particularly suitable candidate for further detailed biological investigations, especially in the treatment of breast cancer.